Agomelatine

Summary

Agomelatine (CHEMBL10878) is an approved small molecule (ATC N06AX22) targeting MTNR1A, MTNR1B, and HTR2A; indicated across 6 conditions including major depressive disorder and depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AX22
• Targets: 5 (MTNR1A, MTNR1B, HTR2A…)
• Indications: 6 conditions
• Clinical trials: 18
• Chemistry: 243.3 Da · C15H17NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL10878
Name	Agomelatine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	82148
ATC	N06AX22
Molecular formula	C15H17NO2
Molecular weight	243.3
InChIKey	YJYPHIXNFHFHND-UHFFFAOYSA-N

SMILES: CC(=O)NCCC1=CC=CC2=C1C=C(C=C2)OC

IUPAC name: N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide

Also known as: Agomelatina, Agomelatine, S-20098, S20098, Thymanax, Valdoxan, agomelatine, AGOMELATINE, SID174006904, SID170466417, AgomelatineÊ, AgomelatineÂ

Patent coverage: 1,398 distinct patent families (4,528 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 4,510 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
MTNR1A	MT1 receptor	Full agonist	10.4	0%	P48039
MTNR1B	MT2 receptor	Full agonist	10.5	0.2%	P49286
HTR2A	5-HT2A receptor	Antagonist	5.4	0%	P28223
HTR2B	5-HT2B receptor	Antagonist	6.6	0.4%	P41595
HTR2C	5-HT2C receptor	Antagonist	6.2	0%	P28335

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Melatonin receptor type 1A, Melatonin receptor type 1B, Melatonin receptor, Melatonin receptor, 5-hydroxytryptamine receptor 2C.

Bioactivity

ChEMBL activities: 52 potent at pChembl ≥ 5 of 54 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MTNR1B	10.38	Ki	0.04	nM	CHEMBL_ACT_28446206
MTNR1A	10.22	Ki	0.06	nM	CHEMBL_ACT_202831
MTNR1A	10.22	Ki	0.06	nM	CHEMBL_ACT_2466319
MTNR1B	10.16	EC50	0.07	nM	CHEMBL_ACT_18001593
MTNR1A	10.12	IC50	0.08	nM	CHEMBL_ACT_632006
MTNR1B	10	Ki	0.1	nM	CHEMBL_ACT_12634715
MTNR1A	10	Ki	0.1	nM	CHEMBL_ACT_12634737
MTNR1A	10	Ki	0.1	nM	CHEMBL_ACT_17957836
MTNR1A	10	Ki	0.1	nM	CHEMBL_ACT_18685691
MTNR1B	10	EC50	0.1	nM	CHEMBL_ACT_202837
MTNR1B	10	EC50	0.1	nM	CHEMBL_ACT_2482278
MTNR1A	10	Ki	0.1	nM	CHEMBL_ACT_25871540
MTNR1B	10	EC50	0.1	nM	CHEMBL_ACT_3290833
MTNR1A	10	Ki	0.1	nM	CHEMBL_ACT_526334
MTNR1A	9.92	Ki	0.12	nM	CHEMBL_ACT_16460965
MTNR1A	9.92	Ki	0.12	nM	CHEMBL_ACT_18001517
MTNR1A	9.92	Ki	0.12	nM	CHEMBL_ACT_22469756
MTNR1B	9.9	Ki	0.13	nM	CHEMBL_ACT_25871541
MTNR1A	9.74	Ki	0.18	nM	CHEMBL_ACT_1099141
MTNR1B	9.74	EC50	0.18	nM	CHEMBL_ACT_16461018
MTNR1B	9.74	EC50	0.18	nM	CHEMBL_ACT_17957891
MTNR1B	9.74	EC50	0.18	nM	CHEMBL_ACT_18685805
MTNR1B	9.7	Ki	0.2	nM	CHEMBL_ACT_17957837
MTNR1A	9.7	EC50	0.2	nM	CHEMBL_ACT_18001592
MTNR1B	9.7	Ki	0.2	nM	CHEMBL_ACT_18685721
MTNR1A	9.7	Ki	0.2	nM	CHEMBL_ACT_28117052
MTNR1A	9.7	Ki	0.2	nM	CHEMBL_ACT_28446203
MTNR1B	9.68	Ki	0.21	nM	CHEMBL_ACT_16460985
MTNR1B	9.68	Ki	0.21	nM	CHEMBL_ACT_22469771
MTNR1B	9.68	EC50	0.21	nM	CHEMBL_ACT_22469804
MTNR1B	9.57	Ki	0.27	nM	CHEMBL_ACT_202832
MTNR1B	9.57	Ki	0.27	nM	CHEMBL_ACT_2466340
MTNR1B	9.42	Ki	0.38	nM	CHEMBL_ACT_18001526
MTNR1B	9.35	Ki	0.45	nM	CHEMBL_ACT_1099142
P49285	9.28	Ki	0.53	nM	CHEMBL_ACT_1099140
P49285	9.27	Ki	0.54	nM	CHEMBL_ACT_1077730
P49285	9.27	Ki	0.54	nM	CHEMBL_ACT_239989
P49285	9.27	Ki	0.54	nM	CHEMBL_ACT_820927
MTNR1A	8.85	EC50	1.4	nM	CHEMBL_ACT_16461004
MTNR1A	8.85	EC50	1.4	nM	CHEMBL_ACT_17957881
MTNR1A	8.85	EC50	1.4	nM	CHEMBL_ACT_18685781
MTNR1A	8.81	EC50	1.56	nM	CHEMBL_ACT_202834
MTNR1A	8.81	EC50	1.56	nM	CHEMBL_ACT_22469782
MTNR1A	8.8	EC50	1.6	nM	CHEMBL_ACT_3290836
P49285	8	EC50	10.1	nM	CHEMBL_ACT_820928
HTR2C	6.2	Ki	630	nM	CHEMBL_ACT_16461060
HTR2C	6.15	Ki	708	nM	CHEMBL_ACT_18001535
HTR2C	6.15	Ki	708	nM	CHEMBL_ACT_18685751
HTR2C	6.15	Ki	708	nM	CHEMBL_ACT_8026533
HTR2B	6.06	AC50	879.5	nM	CHEMBL_ACT_25164127
HTR2B	5.68	AC50	2075	nM	CHEMBL_ACT_25227559
HTR2C	5.28	AC50	5200	nM	CHEMBL_ACT_25131844

Target pathways

Aggregated over 5 target gene(s): MTNR1A, MTNR1B, HTR2A, HTR2B, HTR2C.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	5	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B
Signaling by GPCR	5	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B
Class A/1 (Rhodopsin-like receptors)	5	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B
GPCR downstream signalling	5	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B
GPCR ligand binding	5	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B
Amine ligand-binding receptors	3	HTR2A, HTR2B, HTR2C
Serotonin receptors	3	HTR2A, HTR2B, HTR2C
G alpha (q) signalling events	3	HTR2A, HTR2B, HTR2C
G alpha (i) signalling events	2	MTNR1A, MTNR1B

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	5
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5
signal transduction	5
chemical synaptic transmission	4
intracellular calcium ion homeostasis	3
phospholipase C-activating serotonin receptor signaling pathway	3
serotonin receptor signaling pathway	3
positive regulation of phosphatidylinositol biosynthetic process	3
release of sequestered calcium ion into cytosol	3
positive regulation of ERK1 and ERK2 cascade	3
G protein-coupled serotonin receptor signaling pathway	3
positive regulation of cell population proliferation	2
response to xenobiotic stimulus	2
positive regulation of fat cell differentiation	2
obsolete cGMP-mediated signaling	2

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
major depressive disorder	4	MONDO:0002009	MONDO:0002009
depressive disorder	4	MONDO:0002050	MONDO:0002050

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
obsessive-compulsive disorder	2	MONDO:0008114	EFO:0004242

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE3	9
PHASE4	7
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07011693	PHASE4	NOT_YET_RECRUITING	Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)
NCT01483053	PHASE4	UNKNOWN	Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
NCT01822418	PHASE4	COMPLETED	Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
NCT04181567	PHASE4	COMPLETED	Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
NCT04589143	PHASE4	COMPLETED	A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine
NCT05426304	PHASE4	UNKNOWN	Prophylactic Effects of Agomelatine for Poststroke Depression
NCT05646264	PHASE4	UNKNOWN	A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
NCT00411099	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
NCT00411242	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
NCT00463242	PHASE3	COMPLETED	A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
NCT00467402	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder
NCT01110889	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder
NCT01110902	PHASE3	COMPLETED	Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
NCT01488071	PHASE3	COMPLETED	A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT03852160	PHASE3	WITHDRAWN	A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
NCT00451490	Not specified	WITHDRAWN	The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder
NCT01731899	Not specified	COMPLETED	Agomelatine in Depressed Patients With Fibromyalgia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

566 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
MEBUFOTENIN	ChEMBL	Phase 2	HTR2A, HTR2B, HTR2C, MTNR1A, MTNR1B
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
FIDAXOMICIN	ChEMBL + PubChem	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PIMAVANSERIN	ChEMBL + PubChem	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PROPOXYPHENE	ChEMBL + PubChem	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ALOSETRON	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
AMIODARONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
AMLODIPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
AMOXAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
APOMORPHINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ASENAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ATOMOXETINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
AZATADINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
AZELASTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
BENFLUOREX	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
BENPERIDOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
BENZQUINAMIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
BENZTROPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
BUSPIRONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CANNABIDIOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CARIPRAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CARVEDILOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CINACALCET	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CISAPRIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CITALOPRAM	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CLEMASTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CLOZAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CYCLIZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DAPIPRAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DASATINIB	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DESIPRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DESLORATADINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DICYCLOMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DIMENHYDRINATE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DOMPERIDONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DOTHIEPIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DOXAZOSIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DOXEPIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DROPERIDOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
DULOXETINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
EBASTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ECONAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ENCAINIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ERGOTAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
FLUOXETINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
GUANABENZ	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
GUANFACINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
HALOPERIDOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ILOPERIDONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
IMIPRAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
IPRINDOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
KETANSERIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
KETOTIFEN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
LORCASERIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
LOXAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
LURASIDONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
MAPROTILINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
MELATONIN	ChEMBL	Phase 4 (approved)	HTR2B, MTNR1A, MTNR1B
MEPAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
METHAPYRILENE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
METHYLERGONOVINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
METHYSERGIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
METOCLOPRAMIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
MIANSERIN	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
MICONAZOLE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
MIRTAZAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
NEBIVOLOL	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
NEFAZODONE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
NEFOPAM	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
OLANZAPINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
ORPHENADRINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
OSIMERTINIB	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
OXYPERTINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PERGOLIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PERPHENAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PHENOXYBENZAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PHENTOLAMINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PIMOZIDE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PIPAMAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C
PONATINIB	ChEMBL	Phase 4 (approved)	HTR2A, HTR2B, HTR2C